Danaher Corporation’s Analyst Meeting Review
<p><a href='https://financialmodelingprep.com/financial-summary/DHR'>Danaher Corporation (NYSE:DHR)</a> hosted an in-person analyst meeting last week, providing investors a deeper dive into its portfolio evolution, DBS success stories, and the company’s longer-term targets.</p> 
<p>The company announced its plans to separate its leading Water Quality test/treatment business and Product ID non-contact printing business into a standalone entity by Q4/23.</p>
<p>Analysts at RBC Capital expect the company can over-deliver and orchestrate the separation earlier than the initial target. According to the analysts, the upside in Cepheid COVID testing revenues in Q3/22 was nice to see, and the new long-term targets look achievable to them, especially given underlying market growth in biologics and Danaher’s share gains.</p>

NYSE:DHR